Condition: Central Diabetes Insipidus (cDI) · Sponsor: University Hospital, Basel, Switzerland
This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological symptoms and socio-emotional functioning. Optionally, patients can present for additional assessments in sub-studies: * fMRI sub-study at day 14 (± 2 days) (one additional visit) * Social-stress sub-study at day 14 (± 2 days) (one additional visit)
This description comes directly from the study's public registry record.
Mirjam Christ-Crain, Prof. Dr. med. · +41 61 328 70 80 · mirjam.christ-crain@ubs.ch
Always discuss trial participation with your own doctor first.
| Charité University Medical Center Berlin | Berlin, Germany | Recruiting |
| Erasmus University Medical Center Rotterdam | Rotterdam, Netherlands | Recruiting |
| University Hospital Basel, Department of Endocrinology, Diabetes & Metabolism | Basel, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06036004